Fluge and Mella specifically said they won't put the data out prior to publication, I believe. Now, google of course won't show me where I saw that. But it stuck in my mind for a couple of reasons: 1. disappointment we'd have to wait; but also 2. hope they're expecting to make a great big splash with a very positive result published somewhere very noteworthy.
edit: I may be wrong, because on Reddit, a month ago, someone wrote this:
"My father talked to a researcher in Norway who's been working with Fluge and Mella. He said that he expected the Rituximab results to be revealed before the time of publication in a peer-reviewed journal. This because of how the pharmaceutical company that owns the patent to the medicine will be very eager for more profits and sales, and will be pushing for information, as the CFS patient-group is such a large one globally. He expected the first info to come in Jan/Feb 2018, however the journal article can be delayed for a while after that, depending on how it is received by the peer-reviewers. That's just a guess though, but an educated one at least."